レンチウイルスベクター受託開発・製造機関の世界市場

レンチウイルスベクター受託開発・製造機関の世界市場は2030年までに2億710万米ドルに達する見込み

2024年に1億5,680万米ドルと推定されるレンチウイルスベクター受託開発・製造機関の世界市場は、2030年には2億710万米ドルに達し、分析期間2024-2030年のCAGRは4.7%で成長すると予測されます。本レポートで分析したセグメントの1つであるレンチウイルスプロモーターは、CAGR 6.2%を記録し、分析期間終了時には8,170万米ドルに達すると予測されます。レンチウイルス融合タグセグメントの成長率は、分析期間中CAGR 3.4%と推定されます。

米国市場は4,270万米ドルと推定、中国はCAGR7.8%で成長すると予測

米国のレンチウイルスベクター受託開発・製造機関市場は、2024年に4,270万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 7.8%で推移し、2030年には予測市場規模4,130万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2％と4.8％と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

世界のレンチウイルスベクター受託開発・製造機関（CDMO）市場- 主要動向と促進要因のまとめ

なぜレンチウイルスCDMOはバイオ医薬品エコシステムにおいて戦略的重要性を増しているのか？

レンチウイルスベクター（LVV）の開発・製造受託機関（CDMO）は、生体外遺伝子改変細胞治療で使用されるウイルス送達システムのスケーラブルでコンプライアンスに優れた生産をサポートし、細胞・遺伝子治療産業にとって不可欠な存在になりつつあります。レンチウイルスベクターは一般的に、遺伝子ペイロードを非分裂細胞やゆっくりと分裂する細胞に送達するために使用され、CAR-T細胞療法、遺伝子編集幹細胞、特定の免疫療法コンストラクトの開発に役立っています。自家および同種細胞療法の世界のパイプラインが拡大するにつれ、バイオ製薬企業は、自社でのウイルス製造の複雑さ、規制上の要求、インフラの強度を考慮し、レンチウイルスベクターの供給をCDMOに求めるようになってきています。

特に腫瘍学や希少疾患における承認済みおよび後期段階の遺伝子治療の増加は、レンチウイルスベクターの製造能力に大きなプレッシャーをかけています。規制機関は、厳格なプロセスバリデーション、ウイルスの安全性、GMPグレードの一貫性を義務付けており、CDMOは初期段階の開発から商業規模の生産まで望ましいパートナーとなっています。これらの組織は、FDAのcGMPやEMAのAnnex 2のような厳格な規制の枠組みの下で、プラスミド調製、上流および下流のベクター製造、分析試験、充填仕上げを含むエンドツーエンドのサービスを提供しています。CDMOがベクター開発にもたらす専門知識とインフラは、タイムラインの短縮、スケールアップのリスク回避、進化する品質要件への対応に不可欠です。

プロセス革新とモジュラー・プラットフォームはどのようにレンチウイルス製造サービスを形成していますか？

レンチウイルスベクターの製造は、一過性のトランスフェクションに依存し、収率が低く、精製中のせん断力に敏感であるため、ユニークな課題を抱えています。CDMOは、歩留まりを改善し、コンタミネーションリスクを低減し、バッチサイクルを短縮するために、プロセス強化、クローズドシステムバイオリアクター、クロマトグラフィーベースの精製ワークフローの革新で対応しています。シングルユース技術は現在、上流工程の生産において標準となっており、迅速な切り替え、バリデーション時間の短縮、クロスコンタミネーションの最小化を可能にしています。

モジュラー・プラットフォーム技術は、CDMOが標準化されたアップストリーム／ダウンストリーム・ワークフローを提供することを可能にし、異なる治療薬候補に迅速に適合させることができます。このようなプラットフォームには、HEK293ベースの生産細胞株、無血清培地、PEIベースのトランスフェクションシステム、スケーラブルなろ過/精製ユニットなどが含まれることが多いです。プロセス開発のタイムラインは、実験計画法（DoE）、インライン分析、プロセス分析技術（PAT）の使用により短縮されつつあり、これらは開発の初期段階で重要な品質特性や最適なプロセスパラメーターを特定するのに役立っています。

デジタル化と自動化は、オペレーションをさらに合理化しています。CDMOは、トレーサビリティ、再現性、規制への対応を改善するため、デジタルツイン、電子バッチ記録、AIによる逸脱追跡をGMPスイートに統合しています。これらのデジタルフレームワークは、規制当局がベクターの完全性、空／完全キャプシド比、不定胞体試験に対する監視を強化する中で特に重要です。ベクター製造が実験的規模から商業的規模に移行する中、これらの技術革新は、支払者と規制当局のエコシステムが求める再現性とコスト効率をサポートするために不可欠です。

どのような顧客セグメントと治療モダリティがCDMOとの関わりを促進しているか？

バイオテクノロジー企業、特に初期および中期段階の開発企業は、社内にGMP製造能力を持たないことが多いため、レンチウイルスCDMOの主要な顧客基盤となっています。これらの企業は、前臨床ベクターの供給、IND取得可能なプロセス開発、臨床グレードの製造を扱うCDMOパートナーを求め、治療デザイン、規制戦略、資金調達に集中できるようにしています。後期段階のバイオテクノロジー企業や大手製薬企業も、スケーラブルな能力、地域的な製造拠点、商業上市のための冗長性計画へのアクセスのため、CDMOへの依存度を高めています。

レンチウイルスの需要を牽引する治療分野には、腫瘍学（特にCAR-T療法）、血液疾患（鎌状赤血球症、β-サラセミアなど）、ウィスコット・アルドリッチ症候群やアドレノールコジストロフィーなどの希少遺伝病があります。in vivoでのレンチウイルス応用の台頭は、まだ初期ではあるが、特に製剤技術やターゲティング技術が進歩し、直接投与をサポートするようになれば、CDMOの関与はさらに拡大する可能性があります。さらに、大規模なベクター生産を必要とする同種細胞療法や既製の細胞療法は、大容量のバイオリアクター、凍結保存システム、強固なQCフレームワークを備えた商業的に利用可能な施設に対する需要を生み出しています。

学術機関や病院主導の臨床試験も、ニッチではあるが、特に公的資金がトランスレーショナルリサーチを支援している地域では、成長しつつある顧客グループです。これらのグループは、実験室での研究とヒトでの研究のギャップを埋めるために、GMPベクター生産のために地域のCDMOと提携することが多いです。非営利のコンソーシアム、軍の生物防衛部門、国際保健機関は、特に遺伝子ベースの介入を通じて世界の疾病に対処できるスケーラブルなプラットフォームに対する需要をさらに多様化しています。

何が世界のレンチウイルスベクターCDMO市場の成長を促進しているのか？

世界のレンチウイルスベクターCDMO市場の成長は、遺伝子改変細胞療法の急速な拡大、規制の厳格化、遺伝子治療パイプラインへのベンチャーやバイオファーマの持続的投資など、いくつかの要因によって牽引されています。より多くの遺伝子治療や細胞治療が後期臨床段階に入り、市場認可を得るにつれて、高品質でスケーラブルなレンチウイルスベクターの需要が急増しています。CDMOは、GMP生産をサポートし、市場投入までの時間を短縮し、すべての開発段階を通じて規制コンプライアンスを維持するために、重要な専門知識とインフラを提供します。

製造のボトルネックとベクター施設の高い固定費は、特に商業化前の段階において、開発者をアウトソーシングへと向かわせています。CDMOは、グリーンフィールド投資、買収、技術ライセンシングを通じて生産能力を拡大し、これを活用しています。臨床試験の世界化もCDMOに北米、欧州、アジアでの多地点製造ハブの設立を促し、各地域の規制遵守をサポートし、物流の複雑さを軽減しています。各国政府は、イノベーション助成金、官民パートナーシップ、ATMP関連インフラの迅速な承認を通じて、この拡大を支援しています。

ベクターCDMO、細胞治療開発企業、技術プロバイダー間の戦略的提携は、バリューチェーン全体のイノベーションを促進しています。プラットフォーム技術、デジタルインフラ、ウイルスベクターに関する規制ガイダンスの標準化も、開発の摩擦を減らしています。遺伝子治療資産の強固なパイプラインと規制強化の機運により、レンチウイルスCDMOは持続的な需要拡大の態勢を整えており、個別化医療と再生医療の次の段階において不可欠な存在となっています。

セグメント

コンポーネント（レンチウイルスプロモーター、レンチウイルスフュージョンタグ、レンチウイルスパッケージングシステム、その他のコンポーネント）;疾患適応症（がん、遺伝子疾患、感染症、獣医学的疾患、その他の疾患適応症）;エンドユーザー（製薬・バイオテクノロジー企業エンドユーザー、学術研究エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• AGC Biologics
• Aldevron
• Andelyn Biosciences
• Batavia Biosciences
• BioReliance（Merck KGaA）
• BioVec Pharma
• BOEHRINGER INGELHEIM BioXcellence
• Brammer Bio（Thermo Fisher Scientific）
• Cell and Gene Therapy Catapult
• Charles River Laboratories
• Creative Biogene
• Eurofins CDMO
• Genezen
• IDT Biologika
• Lonza
• Novasep（part of Sartorius）
• Oxford Biomedica
• Sartorius Stedim BioOutsource
• Thermo Fisher Scientific
• Vibalogics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中のドメイン専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Lentiviral Vector Contract Development and Manufacturing Organizations Market to Reach US$207.1 Million by 2030

The global market for Lentiviral Vector Contract Development and Manufacturing Organizations estimated at US$156.8 Million in the year 2024, is expected to reach US$207.1 Million by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Lentiviral Promoter, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$81.7 Million by the end of the analysis period. Growth in the Lentiviral Fusion Tags segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.7 Million While China is Forecast to Grow at 7.8% CAGR

The Lentiviral Vector Contract Development and Manufacturing Organizations market in the U.S. is estimated at US$42.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$41.3 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Lentiviral Vector Contract Development And Manufacturing Organizations (CDMO) Market - Key Trends & Drivers Summarized

Why Are Lentiviral CDMOs Gaining Strategic Significance in the Biotherapeutics Ecosystem?

Lentiviral vector (LVV) contract development and manufacturing organizations (CDMOs) are becoming vital enablers of the cell and gene therapy industry, supporting the scalable and compliant production of viral delivery systems used in ex vivo gene-modified cell therapies. Lentiviral vectors are commonly employed to deliver genetic payloads into non-dividing or slowly dividing cells, making them instrumental in the development of CAR-T cell therapies, gene-edited stem cells, and certain immunotherapy constructs. As the global pipeline of autologous and allogeneic cell therapies expands, biopharma companies are increasingly turning to CDMOs for lentiviral vector supply, given the complexity, regulatory demands, and infrastructure intensity of in-house viral manufacturing.

The rise of approved and late-stage gene therapies, particularly in oncology and rare diseases, is placing acute pressure on lentiviral vector manufacturing capacity. Regulatory agencies mandate rigorous process validation, viral safety, and GMP-grade consistency, making CDMOs the preferred partners for early-stage development through commercial-scale production. These organizations offer end-to-end services including plasmid preparation, upstream and downstream vector production, analytical testing, and fill-finish under stringent regulatory frameworks such as FDA cGMP and EMA Annex 2. The expertise and infrastructure CDMOs bring to vector development are critical to accelerating timelines, de-risking scale-up, and navigating evolving quality requirements.

How Are Process Innovation and Modular Platforms Reshaping Lentiviral Manufacturing Services?

Lentiviral vector production presents unique challenges due to its reliance on transient transfection, low yields, and sensitivity to shear forces during purification. CDMOs are responding with innovations in process intensification, closed-system bioreactors, and chromatography-based purification workflows to improve yield, reduce contamination risks, and shorten batch cycles. Single-use technologies are now standard in upstream production, allowing rapid changeover, reduced validation time, and minimal cross-contamination-especially important for autologous therapies with patient-specific batches.

Modular platform technologies are gaining traction, allowing CDMOs to offer standardized upstream/downstream workflows that can be rapidly adapted to different therapeutic candidates. These platforms often include HEK293-based producer cell lines, serum-free media, PEI-based transfection systems, and scalable filtration/purification units. Process development timelines are being compressed through the use of Design of Experiments (DoE), in-line analytics, and process analytical technology (PAT), which help identify critical quality attributes and optimal process parameters early in development.

Digitalization and automation are further streamlining operations. CDMOs are integrating digital twins, electronic batch records, and AI-assisted deviation tracking into their GMP suites to improve traceability, reproducibility, and regulatory readiness. These digital frameworks are especially important as regulatory bodies tighten oversight on vector integrity, empty/full capsid ratios, and adventitious agent testing. As vector manufacturing shifts from experimental to commercial-scale, these innovations are essential to support the reproducibility and cost-efficiency demanded by payer and regulatory ecosystems.

Which Client Segments and Therapeutic Modalities Are Driving CDMO Engagement?

Biotech firms-particularly early- and mid-stage developers-represent the primary client base for lentiviral CDMOs, as they often lack in-house GMP manufacturing capabilities. These companies seek CDMO partners to handle preclinical vector supply, IND-enabling process development, and clinical-grade manufacturing, allowing them to focus on therapeutic design, regulatory strategy, and fundraising. Late-stage biotech firms and Big Pharma companies are also increasing their reliance on CDMOs to access scalable capacity, regional manufacturing footprints, and redundancy planning for commercial launches.

Therapeutic areas driving lentiviral demand include oncology (notably CAR-T therapies), hematologic disorders (e.g., sickle cell disease, β-thalassemia), and rare genetic diseases such as Wiskott-Aldrich syndrome and adrenoleukodystrophy. The rise of in vivo lentiviral applications-although still early-could expand CDMO engagement further, especially if formulation and targeting technologies advance to support direct administration. Additionally, allogeneic and off-the-shelf cell therapies, which require large-scale vector production, are creating demand for commercial-ready facilities with large-volume bioreactors, cryopreservation systems, and robust QC frameworks.

Academic institutions and hospital-led clinical trials also represent a niche but growing client group, especially in geographies where public funding supports translational research. These groups often partner with regional CDMOs for GMP vector production to bridge the gap between laboratory research and human studies. Non-profit consortia, military biodefense units, and global health agencies are further diversifying the demand base, particularly for scalable platforms that can address global diseases through gene-based interventions.

What Is Fueling Growth in the Lentiviral Vector CDMO Market Worldwide?

The growth in the global lentiviral vector CDMO market is driven by several factors, including the rapid expansion of gene-modified cell therapies, increasing regulatory stringency, and sustained venture and biopharma investment in gene therapy pipelines. As more gene and cell therapies enter late-stage clinical development and gain market authorization, the demand for high-quality, scalable lentiviral vectors is rising sharply. CDMOs provide critical expertise and infrastructure to support GMP production, reduce time to market, and maintain regulatory compliance through all development phases.

Manufacturing bottlenecks and the high fixed cost of vector facilities are pushing developers toward outsourcing, especially in the pre-commercial phase. CDMOs are capitalizing on this by expanding capacity through greenfield investments, acquisitions, and technology licensing. Globalization of clinical trials is also encouraging CDMOs to establish multipoint manufacturing hubs in North America, Europe, and Asia to support regional regulatory compliance and reduce logistical complexity. Governments are supporting this expansion through innovation grants, public-private partnerships, and expedited approvals for ATMP-related infrastructure.

Strategic collaborations between vector CDMOs, cell therapy developers, and technology providers are fostering innovation across the value chain. Standardization of platform technologies, digital infrastructure, and regulatory guidance for viral vectors are also reducing development friction. With a robust pipeline of gene therapy assets and growing regulatory momentum, lentiviral CDMOs are poised for sustained demand growth, making them indispensable players in the next phase of personalized and regenerative medicine.

SCOPE OF STUDY:

The report analyzes the Lentiviral Vector Contract Development and Manufacturing Organizations market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems, Other Components); Disease Indication (Cancer, Genetic Disorders, Infectious Diseases , Veterinary Disease, Other Disease Indications); End-User (Pharmaceutical & Biotechnology Company End-User, Academic Research End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AGC Biologics
• Aldevron
• Andelyn Biosciences
• Batavia Biosciences
• BioReliance (Merck KGaA)
• BioVec Pharma
• BOEHRINGER INGELHEIM BioXcellence
• Brammer Bio (Thermo Fisher Scientific)
• Cell and Gene Therapy Catapult
• Charles River Laboratories
• Creative Biogene
• Eurofins CDMO
• Genezen
• IDT Biologika
• Lonza
• Novasep (part of Sartorius)
• Oxford Biomedica
• Sartorius Stedim BioOutsource
• Thermo Fisher Scientific
• Vibalogics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Lentiviral Vector Contract Development and Manufacturing Organizations - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Accelerated Growth in Cell and Gene Therapy Pipelines Spurs Demand for Lentiviral Vector CDMOs
  • Rising Complexity in Vector Engineering Throws the Spotlight on Specialized CDMO Capabilities
  • Expansion of Clinical Trials for CAR-T and Rare Disease Therapies Propels Vector Manufacturing Contracts
  • Surge in Biotech Startups with Limited Manufacturing Infrastructure Strengthens CDMO Outsourcing
  • FDA and EMA Emphasis on GMP Compliance Drives Process Standardization and Facility Certifications
  • Growing Need for Scalable, High-Titer Vector Production Expands CDMO Engagement in Late-Stage Programs
  • Increase in Platform Technologies for Lentiviral Production Enhances Speed-to-Market for Biologics
  • Strategic Partnerships Between Biopharma and CDMOs Propel Tech Transfer and IP Sharing
  • Shift Toward Suspension-Based Manufacturing Systems Spurs Facility and Platform Modernization
  • Development of Single-Use Bioreactors and Closed Systems Strengthens CDMO Process Offerings
  • Outsourcing of Analytics and Fill-Finish Services Drives End-to-End Lentiviral Vector Solutions
  • Increased Cell Therapy Commercialization Activity Expands Long-Term Manufacturing Contracts
  • OEM-CDMO Integration Trends Streamline Supply Chain and Quality Control in Vector Production
  • Emergence of Modular and POD-Based Facilities Enables Rapid CDMO Capacity Expansion
  • High Capital Intensity of In-House Vector Production Drives Outsourcing Among Mid-Sized Firms
  • Global Focus on Orphan Disease and Rare Genetic Disorder Therapies Sustains Demand for Custom Lentiviral Vectors
  • Regulatory Pressure for Viral Safety and Purity Testing Enhances Quality Assurance Capabilities
  • Shortage of GMP-Qualified CDMO Slots Creates Capacity Bottlenecks and Price Premiums
  • Technology Licensing Models for Viral Vector Platforms Expand CDMO Revenue Streams
  • Globalization of Cell Therapy Markets Generates Opportunities for Regional CDMO Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Lentiviral Vector Contract Development and Manufacturing Organizations Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Lentiviral Promoter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Lentiviral Promoter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Lentiviral Promoter by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lentiviral Fusion Tags by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lentiviral Fusion Tags by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Lentiviral Fusion Tags by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Lentivirus Packaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Lentivirus Packaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Lentivirus Packaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Company End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharmaceutical & Biotechnology Company End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Pharmaceutical & Biotechnology Company End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic Research End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Academic Research End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Academic Research End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Veterinary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Veterinary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Veterinary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• JAPAN
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• CHINA
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• EUROPE
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• FRANCE
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• GERMANY
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• INDIA
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030
• AFRICA
  • Lentiviral Vector Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Component - Percentage Breakdown of Value Sales for Lentiviral Promoter, Lentiviral Fusion Tags, Lentivirus Packaging Systems and Other Components for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by End-user - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Company End-User, Academic Research End-User and Other End-Users for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Lentiviral Vector Contract Development and Manufacturing Organizations by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other Disease Indications for the Years 2014, 2025 & 2030

IV. COMPETITION